• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌中的脂质代谢重编程

Lipid Metabolic Reprogramming in Hepatocellular Carcinoma.

作者信息

Nakagawa Hayato, Hayata Yuki, Kawamura Satoshi, Yamada Tomoharu, Fujiwara Naoto, Koike Kazuhiko

机构信息

Department of Gastroenterology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

出版信息

Cancers (Basel). 2018 Nov 15;10(11):447. doi: 10.3390/cancers10110447.

DOI:10.3390/cancers10110447
PMID:30445800
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6265967/
Abstract

Metabolic reprogramming for adaptation to the local environment has been recognized as a hallmark of cancer. Although alterations in fatty acid (FA) metabolism in cancer cells have received less attention compared to other metabolic alterations such as glucose or glutamine metabolism, recent studies have uncovered the importance of lipid metabolic reprogramming in carcinogenesis. Obesity and nonalcoholic steatohepatitis (NASH) are well-known risk factors of hepatocellular carcinoma (HCC), and individuals with these conditions exhibit an increased intake of dietary FAs accompanied by enhanced lipolysis of visceral adipose tissue due to insulin resistance, resulting in enormous exogenous FA supplies to hepatocytes via the portal vein and lymph vessels. This "lipid-rich condition" is highly characteristic of obesity- and NASH-driven HCC. Although the way in which HCC cells adapt to such a condition and exploit it to aid their progression is not understood, we recently obtained new insights into this mechanism through lipid metabolic reprogramming. In addition, accumulating evidence supports the importance of lipid metabolic reprogramming in various situations of hepatocarcinogenesis. Thus, in this review, we discuss the latest findings regarding the role of FA metabolism pathways in hepatocarcinogenesis, focusing on obesity- and NASH-driven lipid metabolic reprogramming.

摘要

代谢重编程以适应局部环境已被公认为癌症的一个标志。尽管与葡萄糖或谷氨酰胺代谢等其他代谢改变相比,癌细胞中脂肪酸(FA)代谢的改变受到的关注较少,但最近的研究揭示了脂质代谢重编程在致癌过程中的重要性。肥胖和非酒精性脂肪性肝炎(NASH)是肝细胞癌(HCC)众所周知的危险因素,患有这些疾病的个体由于胰岛素抵抗,膳食脂肪酸摄入量增加,同时内脏脂肪组织的脂肪分解增强,导致通过门静脉和淋巴管向肝细胞大量供应外源性脂肪酸。这种“富含脂质的状态”是肥胖和NASH驱动的HCC的高度特征。尽管HCC细胞如何适应这种状态并利用它来促进其进展尚不清楚,但我们最近通过脂质代谢重编程对这一机制有了新的认识。此外,越来越多的证据支持脂质代谢重编程在肝癌发生的各种情况下的重要性。因此,在本综述中,我们讨论了脂肪酸代谢途径在肝癌发生中的作用的最新发现,重点是肥胖和NASH驱动的脂质代谢重编程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6dd/6265967/e3a93ec20fce/cancers-10-00447-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6dd/6265967/c1954a2790dc/cancers-10-00447-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6dd/6265967/e3a93ec20fce/cancers-10-00447-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6dd/6265967/c1954a2790dc/cancers-10-00447-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6dd/6265967/e3a93ec20fce/cancers-10-00447-g002.jpg

相似文献

1
Lipid Metabolic Reprogramming in Hepatocellular Carcinoma.肝细胞癌中的脂质代谢重编程
Cancers (Basel). 2018 Nov 15;10(11):447. doi: 10.3390/cancers10110447.
2
CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.CPT2 下调使 HCC 适应富含脂质的环境,并通过肥胖症中酰基辅酶 A 的积累促进癌变。
Gut. 2018 Aug;67(8):1493-1504. doi: 10.1136/gutjnl-2017-315193. Epub 2018 Feb 6.
3
Nonalcoholic fatty liver disease and hepatocellular carcinoma.非酒精性脂肪性肝病与肝细胞癌
Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23.
4
Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies.非酒精性脂肪性肝炎-肝细胞癌涉及的流行病学、遗传学、致病性、代谢、表观遗传学方面:当前治疗策略
Cancers (Basel). 2022 Dec 20;15(1):23. doi: 10.3390/cancers15010023.
5
Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma.脂质代谢在肝细胞癌发生发展中的作用
Cancers (Basel). 2020 May 31;12(6):1419. doi: 10.3390/cancers12061419.
6
Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review.肝细胞癌细胞中的异常脂质代谢和免疫微环境:综述。
Cell Prolif. 2020 Mar;53(3):e12772. doi: 10.1111/cpr.12772. Epub 2020 Jan 31.
7
Obesity, insulin resistance, NASH and hepatocellular carcinoma.肥胖症、胰岛素抵抗、非酒精性脂肪性肝炎和肝细胞癌。
Semin Cancer Biol. 2013 Dec;23(6 Pt B):483-91. doi: 10.1016/j.semcancer.2013.07.003. Epub 2013 Jul 19.
8
Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight.代谢功能障碍相关脂肪性肝病诱导的肝细胞癌中表观遗传学与代谢重编程之间的串扰:新视角
Metabolites. 2024 Jun 8;14(6):325. doi: 10.3390/metabo14060325.
9
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.非酒精性脂肪性肝病/非酒精性脂肪性肝炎与肝细胞癌。
Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.
10
Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis.肥胖和非酒精性脂肪性肝炎相关肝癌发生的小鼠模型的最新进展
World J Hepatol. 2015 Aug 18;7(17):2110-8. doi: 10.4254/wjh.v7.i17.2110.

引用本文的文献

1
Mitochondrial dysfunction in hepatocellular carcinoma: from metabolism to targeted therapies.肝细胞癌中的线粒体功能障碍:从代谢到靶向治疗
Mol Cell Biochem. 2025 Aug 30. doi: 10.1007/s11010-025-05377-x.
2
Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications.肝细胞癌中的代谢重编程:免疫逃逸机制及治疗意义
Front Immunol. 2025 Apr 30;16:1592837. doi: 10.3389/fimmu.2025.1592837. eCollection 2025.
3
Lipogenesis and MASLD: re-thinking the role of SREBPs.脂肪生成与代谢相关脂肪性肝病:重新审视固醇调节元件结合蛋白的作用

本文引用的文献

1
Integrative genomic analysis of mouse and human hepatocellular carcinoma.整合分析小鼠和人肝癌的基因组。
Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):E9879-E9888. doi: 10.1073/pnas.1811029115. Epub 2018 Oct 4.
2
Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma.磷酸化或抑制剂 ND-654 抑制乙酰辅酶 A 羧化酶可抑制脂肪生成和肝癌。
Cell Metab. 2019 Jan 8;29(1):174-182.e5. doi: 10.1016/j.cmet.2018.08.020. Epub 2018 Sep 20.
3
How endoplasmic reticulum stress contributes to obesity-driven hepatic tumorigenesis.
Arch Toxicol. 2025 May 6. doi: 10.1007/s00204-025-04052-w.
4
The Role of the Hexosamine-Sialic Acid Metabolic Pathway Mediated by GFPT1/NANS in c-Myc-Driven Hepatocellular Carcinoma.由GFPT1/NANS介导的己糖胺-唾液酸代谢途径在c-Myc驱动的肝细胞癌中的作用
Cell Mol Gastroenterol Hepatol. 2025 Apr 24;19(9):101523. doi: 10.1016/j.jcmgh.2025.101523.
5
IRX5 Promoted SREBP1-Mediated de Novo Fatty Acid Synthesis via HMGN4 in Hepatocellular Carcinoma.IRX5通过HMGN4促进肝细胞癌中SREBP1介导的从头脂肪酸合成
J Cell Mol Med. 2025 Apr;29(7):e70441. doi: 10.1111/jcmm.70441.
6
Construction of a prognostic signature for breast cancer based on genes involved in unsaturated fatty acid biosynthesis.基于参与不饱和脂肪酸生物合成的基因构建乳腺癌预后特征。
Transl Cancer Res. 2025 Feb 28;14(2):1190-1204. doi: 10.21037/tcr-24-1668. Epub 2025 Feb 24.
7
Deciphering the metabolic landscape of colorectal cancer through the lens of AhR-mediated intestinal inflammation.通过芳烃受体介导的肠道炎症视角解读结直肠癌的代谢格局。
Discov Oncol. 2025 Mar 7;16(1):275. doi: 10.1007/s12672-025-01949-x.
8
Dysregulation of the SREBP pathway is associated with poor prognosis and serves as a potential biomarker for the diagnosis of hepatocellular carcinoma.固醇调节元件结合蛋白(SREBP)信号通路失调与预后不良相关,并可作为诊断肝细胞癌的潜在生物标志物。
Mol Med Rep. 2025 May;31(5). doi: 10.3892/mmr.2025.13477. Epub 2025 Feb 28.
9
The association between Clonorchis sinensis seropositivity and hepatocellular carcinoma in an endemic area: a study in Guangxi, China.华支睾吸虫血清阳性与某流行地区肝细胞癌之间的关联:中国广西的一项研究
BMC Infect Dis. 2025 Feb 25;25(1):270. doi: 10.1186/s12879-025-10675-2.
10
Integrated single-cell and bulk transcriptome analysis of R-loop score-based signature with regard to immune microenvironment, lipid metabolism and prognosis in HCC.基于R环评分的特征在肝癌免疫微环境、脂质代谢及预后方面的单细胞与批量转录组综合分析
Front Immunol. 2025 Jan 9;15:1487372. doi: 10.3389/fimmu.2024.1487372. eCollection 2024.
内质网应激如何促进肥胖驱动的肝脏肿瘤发生。
Hepat Oncol. 2015 Jul;2(3):209-211. doi: 10.2217/hep.15.11. Epub 2015 Jul 30.
4
Histone variant macroH2A1 rewires carbohydrate and lipid metabolism of hepatocellular carcinoma cells towards cancer stem cells.组蛋白变体宏 H2A1 重塑肝癌细胞的碳水化合物和脂质代谢以促进肿瘤干细胞。
Epigenetics. 2018;13(8):829-845. doi: 10.1080/15592294.2018.1514239. Epub 2018 Sep 29.
5
Molecular therapies and precision medicine for hepatocellular carcinoma.肝细胞癌的分子治疗和精准医学。
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616. doi: 10.1038/s41571-018-0073-4.
6
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.GS-0976 可降低非酒精性脂肪性肝病患者的肝脂肪变性和纤维化标志物。
Gastroenterology. 2018 Nov;155(5):1463-1473.e6. doi: 10.1053/j.gastro.2018.07.027. Epub 2018 Jul 27.
7
Metabolic traits of cancer stem cells.肿瘤干细胞的代谢特征。
Dis Model Mech. 2018 Jun 28;11(8):dmm033464. doi: 10.1242/dmm.033464.
8
Cancer Stem Cell Metabolism and Potential Therapeutic Targets.癌症干细胞代谢与潜在治疗靶点
Front Oncol. 2018 Jun 5;8:203. doi: 10.3389/fonc.2018.00203. eCollection 2018.
9
Downregulation of CPT2 promotes tumorigenesis and chemoresistance to cisplatin in hepatocellular carcinoma.CPT2的下调促进肝细胞癌的肿瘤发生及对顺铂的化疗耐药。
Onco Targets Ther. 2018 May 25;11:3101-3110. doi: 10.2147/OTT.S163266. eCollection 2018.
10
Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance.癌症脂代谢赋予抗血管生成药物耐药性。
Cell Metab. 2018 Jul 3;28(1):104-117.e5. doi: 10.1016/j.cmet.2018.05.005. Epub 2018 May 31.